(Q45090161)

9 December 2017

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer (English)

1 reference

9 December 2017

phase II clinical trial

0 references

1 reference

5

1 reference

9 December 2017

Donald S Kaufman

1

1 reference

9 December 2017

Michael A Carducci

2

1 reference

9 December 2017

Tim M Kuzel

3

1 reference

9 December 2017

Mary B Todd

4

1 reference

9 December 2017

Matthew R Smith

6

1 reference

9 December 2017

Zhishen Ye

7

1 reference

9 December 2017

Steven J Nicol

8

1 reference

9 December 2017

Walter M Stadler

9

1 reference

9 December 2017

1 September 2004

1 reference

9 December 2017

1 reference

9 December 2017

22

1 reference

9 December 2017

393-397

1 reference

9 December 2017

5

1 reference

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

9 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Pharmacokinetics of paclitaxel in an anephric patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.002

10.1016/J.UROLONC.2004.01.002

7 January 2021

Identifiers

DOI

1 reference

9 December 2017

1 reference